Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 0.17 GBp
Change Today 0.00 / 0.00%
Volume 481.3K
EVO On Other Exchanges
As of 11:30 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

evocutis plc (EVO) Snapshot

0.17 GBp
Previous Close
0.17 GBp
Day High
0.17 GBp
Day Low
0.17 GBp
52 Week High
09/1/14 - 1.29 GBp
52 Week Low
08/20/14 - 0.16 GBp
Market Cap
Average Volume 10 Days
-0.0008 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOCUTIS PLC (EVO)

Related News

No related news articles were found.

evocutis plc (EVO) Related Businessweek News

No Related Businessweek News Found

evocutis plc (EVO) Details

Evocutis plc does not have significant operations. The company intends to invest in and/or acquire companies and/or projects within the natural resources sector. Previously, it engaged in the provision of skin microbiology and clinical dermatology services to companies in the pharmaceutical and consumer healthcare markets. The company was formerly known as Syntopix Group plc and changed its name to Evocutis plc in October 2011. Evocutis plc was incorporated in 2005 and is based in London, the United Kingdom. As of March 19, 2014, Evocutis plc operates as a subsidiary of Venn Life Sciences Holding plc.

4 Employees
Last Reported Date: 01/21/15
Founded in 2005

evocutis plc (EVO) Top Compensated Officers

Interim Chief Executive Officer
Total Annual Compensation: 45.0K GBP
Chief Financial Officer and Group Finance Dir...
Total Annual Compensation: 3.0K GBP
Compensation as of Fiscal Year 2014.

evocutis plc (EVO) Key Developments

Evocutis plc Provides Independent Assessment of Horse Hill Licences

Further to the report provided to UK Oil & Gas Investments plc by Nutech in relation to the Horse Hill-1 well in the Weald basin, previously announced in April 2015, Evocutis plc has been advised that Nutech has now provided an independent report of the oil initially in place ('OIP') contained within 55 square miles covered by the Horse Hill licences (PEDL137 and PEDL246) near Gatwick Airport, south of London. This evaluation does not include the OIP for the Portland Sandstones, which has already been evaluated and reported on. The study calculates that the total Jurassic shale plus tight conventional reservoir section of UKOG's licences contain a Best Estimate, or P50, OIP of 9,245 million barrels. The Nutech OIP study presents the results of a 3D geological and petrophysical static model used to calculate the range of possible OIP over the 55 square mile PEDL137 and PEDL246 licenses in the UK Weald Basin. The study utilises new 2015 analyses of the HH-1 and Collendean Farm-1 wells and the 8 closest wells to the licenses, together with NUTECH's existing 2014 regional 3D Weald basin framework of 114 wells. The Horse Hill-1 well is located within onshore exploration License PEDL137, on the northern side of the Weald Basin near Gatwick Airport. Evocutis owns a 2% direct interest in Horse Hill Developments Ltd. HHDL is a special purpose company that owns 65% participating interests and is the operator of licence PEDL137 and the adjacent licence PEDL246 in the UK Weald Basin. The remaining 35% participating interests in the PEDL137 and PEDL246 licenses are held by Magellan Petroleum Corporation.

Evocutis plc, Annual General Meeting, May 21, 2015

Evocutis plc, Annual General Meeting, May 21, 2015., at 16:00 GMT Standard Time. Location: 200 Strand.

Evocutis plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended January 31, 2014

Evocutis plc announced unaudited consolidated earnings results for the six months ended January 31, 2014. For the year, the company reported loss before taxation was £57,000 against £67,000 a year ago. Loss for the period from continuing operations was £57,000 against £67,000 a year ago. Loss for the period and total comprehensive loss attributable to equity shareholders was £62,000 against £422,000 a year ago. Basic and diluted loss per ordinary share from continuing operations was 0.01 pence against 0.04 pence a year ago. Net cash flows used in operating activities was £303,000 against £387,000 a year ago. Payment to acquire intangible assets was £164,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVO:LN 0.17 GBp 0.00

EVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVO.
View Industry Companies

Industry Analysis


Industry Average

Valuation EVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOCUTIS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at